Fotantinib/Fotantinib is produced by which pharmaceutical company?

Fostamatinib is an oral small molecule drug developed and produced by Rigel Pharmaceuticals in the United States. Its main mechanism of action is to regulate the body's immune response by inhibiting the spleen tyrosine kinase (SYK) signaling pathway. Rigel is a biopharmaceutical company focused on immunology and rare disease treatments. The company is committed to developing innovative treatments for unmet clinical needs, and fotantinib is one of its most representative marketed drugs.

The drug was first approved by the US FDA in 2018 for the treatment of chronic immune thrombocytopenia (ITP) in adults, especially those who do not respond well to first-line treatments such as glucocorticoids or immunoglobulins. Subsequently, fotantinib was also approved by the European Medicines Agency and was marketed under the trade name TAVALISSE in Germany, the United Kingdom and other countries.

The launch of fotantinib not only marksRigel’s success in the development of innovative drugs, but also brings new treatment options to patients with immune thrombocytopenia. By blocking SYK signaling, the drug effectively intervenes in the platelet destruction process caused by autoimmune reactions, thereby increasing platelet counts and reducing the risk of bleeding. Due to its unique mechanism of action, fotantinib is also considered by researchers as a potential drug candidate for the treatment of other autoimmune diseases. Rigel is currently exploring the application prospects of this drug in multiple indications such as rheumatic diseases, anemia, and autoimmune nephropathy, showing its broad development potential in the field of immune regulation.

It is worth mentioning that although fotantinib has been approved for marketing in many countries, its accessibility in the global market is still subject to certain restrictions. For example, in China and other regions, the drug has not yet been officially approved for marketing or included in the medical insurance system, and there are no generic drugs on the market. If patients want to use it, they need to import the original version through specific channels.

Reference materials:https://go.drugbank.com/drugs/DB12010